23andMe Garners $115,000,000 Series E Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2beb7170-1a2f-49f4-b3d3-c06a6107f3ad - Date
10/14/2015 - Company Name
23andMe - Mailing Address
1390 Shorebird Way Mountain View, CA 94043 USA - Company Description
23andMe is focused on empowering individuals to access, explore, and better understand their genetic information, making use of recent advances in DNA analysis technologies and proprietary web-based software tools. - Website
http://www.23andme.com - Transaction Type
Venture Equity - Transaction Amount
$115,000,000 - Transaction Round
Series E - Proceeds Purposes
This round of funding will enable us to further our vision for long term growth in our consumer and therapeutic businesses. This investment will enable the company to expand its operations and maximize the potential of its direct-to-consumer product in the US and abroad. The company expects to launch a new user experience that includes carrier status reports in the US, as well as enhanced tools and functionality for customers by the end of the year. The Series E financing will also provide capital for strategic infrastructure including new laboratory space for therapeutic research, a next generation sequencing laboratory as well as other investments in long-term growth. - M&A Terms
- Venture Investor
Fidelity Management & Research Company - Venture Investor
Casdin Capital - Venture Investor
WuXi PharmaTech - Venture Investor
Xfund - Venture Investor
Illumina - Venture Investor
New Enterprise Associates - Venture Investor
MPM Capital - Venture Investor
Google Ventures
